Navigation Links
NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan
Date:10/25/2007

BEDMINSTER, N.J., Oct. 25 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today the approval of cinacalcet hydrochloride by the Japanese Pharmaceuticals and Medical Devices Agency for the treatment of secondary hyperparathyroidism. As a result, NPS will receive a milestone payment plus royalties from Kirin Pharma, a wholly owned subsidiary of Kirin Holdings, which will market the drug in Japan. Kirin licensed cinacalcet from NPS in 1995 for development and commercial sale in Japan, China, North and South Korea, and Taiwan.

Cinacalcet is an oral medication for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. It regulates the over-secretion of parathyroid hormone (PTH) in patients with chronic kidney insufficiency by acting directly on the parathyroid gland calcium-sensing receptor. Elevated levels of PTH, the hallmark of secondary hyperparathyroidism, are associated with altered metabolism of calcium and phosphorus, bone pain, fractures, and an increased risk for cardiovascular death. The drug is currently marketed in the United States and Europe by Amgen as a treatment for this condition and for the treatment of elevated levels of calcium in patients with parathyroid carcinoma.

NPS president and CEO Dr. Tony Coles stated: "We congratulate our partner Kirin Pharma for obtaining approval to market cinacalcet in Japan as a treatment for secondary hyperparathyroidism. This first-in-class compound treats a serious complication of chronic kidney disease for which patients in Japan with this condition have had no therapeutic alternative."

Kirin Pharma general manager of strategic product planning, T. Oishi, stated: "Approximately 30 to 40 % of dialysis patients in Japan have secondary hyperparathyroidism. The results of our clinical studies have demonstrated significant benefits of daily administration of cinacalcet in individuals with this serious condition. We look forward to bringing this drug to patients in Japan."

About NPS

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.

Note: Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of October 25, 2007 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended June 30, 2007.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... and READING, England ... Indegene ( http://www.indegene.com ), ein führender ... für die Life-Science-Branche, Pharmaunternehmen und Gesundheitsorganisationen, und ... Anbieter von innovativen wissenschaftlichen Support-Services für den ... von IntraScience heute den Ausbau ihrer bestehenden ...
(Date:5/26/2016)... and READING, England ... Indegene ( http://www.indegene.com ), a leading global provider ... science, pharmaceutical and healthcare organisations and TranScrip ( ... scientific support throughout the product lifecycle, today announced ... launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising ... at the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular ... US earlier this year following FDA approval of a second application for a ...
(Date:5/25/2016)... ... , ... Lajollacooks4u has become a rising hotspot for specialized team building events ... attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have traveled ... , Each event kicks off with an olive oil and salt-tasting competition. From ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
Breaking Biology News(10 mins):